AbbVie Inc. (ABBV) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for AbbVie Inc. (ABBV:NYSE), powered by AI.
- Current Price
- $208.84
- Market Cap
- 369.1B
- Sector
- Healthcare
What is the AbbVie Inc. stock price forecast?
AbbVie Inc. is currently trading at $208.84. View real-time AI analysis on Alpha Lenz.
What is AbbVie Inc. insider trading activity?
View the latest insider trading data for AbbVie Inc. on Alpha Lenz.
What is AbbVie Inc.'s P/E ratio?
View AbbVie Inc.'s valuation metrics on Alpha Lenz.
AbbVie Inc.
Company Overview
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.